Autres langues FibroGen, Inc.

Actions

FGEN

US31572Q8087

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
1,09 ^USD	+4,81 %		-4,39 %	+22,98 %

24/04	FibroGen, Inc. présentera les données cliniques de l'étude de phase 1B à doses croissantes du FG-3246 (FOR46) en association avec l'enzalutamide chez des patients atteints d'un cancer de la prostate métastatique résistant à la castration lors du congrès annuel de l'American Society of Clinical Oncology en 2024.	CI
15/04	Faron Pharmaceuticals reconduit par intérim son ancien directeur financier	AN

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

FibroGen to Report First Quarter 2024 Financial Results	13:00
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting	24/04
FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting	24/04
Faron Pharmaceuticals reappoints former finance chief on interim basis	15/04
Top Midday Decliners	03/04
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise	03/04
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	02/04
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	02/04
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference	26/03
FibroGen : Corporate Presentation – March 2024	19/03
Sector Update: Health Care Stocks Rise Late Afternoon	12/03
Sector Update: Health Care Stocks Higher in Afternoon Trading	12/03
FibroGen Shares Jump After CEO Stock Purchase	12/03
FibroGen Names Deyaa Adib Chief Medical Officer	11/03
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer	11/03
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer	11/03
FibroGen : Corporate Presentation – March 2024	06/03
FibroGen: Q4 Earnings Snapshot	26/02
FibroGen regains rights to anemia drug from AstraZeneca	26/02
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues FibroGen, Inc.

Actions

FGEN

US31572Q8087

Autres langues

Filtres